海思科：关于获得创新药《药物临床试验批准通知书》的公告

Core Viewpoint - The company, Haishi Ke, announced that its subsidiary, Shanghai Haishi Shengnuo Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of four drug candidates [2] Group 1: Clinical Trial Approvals - The approved drug candidates include HSK45019 tablets, HSK50042 tablets, injectable HSK55718, and HSK36357 capsules [2] - The clinical trial applications were reviewed and found to meet the requirements for drug registration, allowing the company to proceed with the trials [2] - The approval is significant as it indicates progress in the company's drug development pipeline, with trials set to be conducted starting from October 2025 [2]